LONDON, August 16, 2017 /PRNewswire/ --
Endometriosis - our new study reveals trends, R&D progress, and predicted revenues
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
Where is the Endometriosis market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.
Discover How to Stay Ahead:
Our 146-page report provides 108 tables, charts, clearly illustrating the data presented in this research. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted drug sales at overall world market regional level, as well as giving a deep insight into the pipeline for Endometriosis. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Endometriosis market. See how to exploit the opportunities.
Forecasts to 2027 and other analyses reveal the commercial prospects
In addition to revenue forecasting to 2027, our new study provides you with recent results, R&D overview, growth rates, and market shares.
You find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and following Endometriosis Therapeutics:
Lupron
Eligard
Zoladex
Depo-Provera
Visanne
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 11 leading national markets:
The US
Germany
France
The UK
Spain
Italy
Japan
China
India
Brazil
Russia
RoW
Endometriosis Drug Forecasts and R&D 2017-2027
The report also includes profiles and pipeline analysis for some of the leading companies in the Endometriosis market, with a focus on the Endometriosis segment of these companies' operations.
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, Germany, France and India in particular, will continue to achieve high revenue growth to 2027.
Leading companies and the potential for market growth
Overall world revenue for Endometriosis will surpass $3bn in 2027, our work calculates. This will be driven by the development of more effective drugs for the condition as well as raising awareness of Endometriosis over the forecast period
Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Endometriosis Market report helps you
In summary, our 146-page report provides you with the following knowledge:
Revenue forecasts to 2027 for the Endometriosis market and 5 Leading Therapeutic Drugs for the condition - discover the industry's prospects, finding the most lucrative places for investments and revenues
Revenue forecasts to 2027 for 11 of the leading national markets - US, Germany, France, UK, Italy, Spain, Russia, Japan, China, India, Brazil
Discussion of what stimulates and restrains companies and the market
Prospects for established firms and those seeking to enter the market - including company profiles and R&D overviews for 10 companies involved in developing and manufacturing Endometriosis drugs
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the Endometriosis market and leading companies. You will find data, trends and predictions.
Get our report today Endometriosis Drug Forecasts and R&D 2017-2027: Forecasts and Analysis of Leading Endometriosis Drugs (Lupron, Eligard, Zoladex, Depo-Provera, Visanne), Companies and Key National Markets. Avoid missing out - get our report now.
To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100
Or click on https://www.visiongain.com/Report/1957/Endometriosis-Drug-Forecasts-and-R-D-2017-2027
Companies Mentioned in This Report:
Abbott Laboratories
AbbVie
Ablynx NV
AC Immune SA
Active Biotech AB
Addex Therapeutics Ltd.
Advanced Biological Laboratories SA
AEterna Zenaris
Agenus Schweiz AG
Agios Pharmaceuticals, Inc.
Aileron Therapeutics, Inc.
Akari Therapeutics Plc
Allergan Plc
Amanouchi Pharmaceutical Co.
Amgen, Inc.
Anacor Pharmaceuticals, Inc.
AP Avadis Biotechnologies
Apeiron Biologics Ag
Apogenix GmbH
Aquinox Pharmaceuticals, Inc.
ArQule, Inc.
Array BioPharma, Inc.
Astellas Pharma
AstraZeneca Plc
Atrix Laboratories
Bayer HealthCare
BeiGene Ltd.
BioAtla LLC
Biogen, Inc.
BioNTech AG
BioPorto A/S
Bio-Rad Laboratories, Inc.
Celgene Corp.
Celmatix Inc.
CEL-SCI Corp.
Cepheid
Cidara Therapeutics, Inc.
Cogstate Ltd.
Collplant Holdings Ltd.
CRISPR Therapeutics AG
CTI BioPharma Corp.
Cyprotex Plc
CytomX Therapeutics, Inc.
Debiopharm International Sa
DelsiTech Ltd.
Domain Therapeutics SA
Dongkook Pharmaceutical Co.
ElexoPharm GmbH
Eli Lilly
Enanta Pharmaceuticals, Inc.
EndoCeutics
Epizyme, Inc.
Euroscreen S.A.
Euthymics Bioscience Inc.
Evotec AG
Florida Hospital
Fujisawa Pharmaceutical Co.
Genentech, Inc.
Genzyme Corporation
GlaxoSmithKline
Halozyme Therapeutics, Inc.
HemoShear Therapeutics LLC
Highland Clinical Research
Hydra Biosciences Inc.
Idera Pharmaceuticals, Inc.
ImmunoGen, Inc.
Immunomedics, Inc.
Inc. Forendo Pharma Oy
Infinity Pharmaceuticals, Inc.
Interleukin Genetics, Inc.
Invivo Therapeutics Holdings Corp.
Isifer AB
Jiangsu Kanion Pharmaceutical Co.
Kissei Pharmaceutical
Lipicard Technologies Limited
Medigene AG
Meditrina Pharmaceuticals
Medivation, Inc.
Mendel Biotechnology Inc.
MorphoSys AG
Mylan NV
Myovant Sciences Ltd.
Neurocrine Biosciences, Inc.
NextCure Inc.
ObsEva
OncoMed Pharmaceuticals, Inc.
OncoTherapy Science, Inc.
OPKO Health, Inc.
Orphagen Pharmaceuticals
Peptidream Inc.
Pfizer
Philogen
Philogen Spa
Portola Pharmaceuticals, Inc.
PregLem SA
Probiodrug AG
pSivida Corp.
Puma Biotechnology, Inc.
Repros Therapeutics Inc.
Roche
Sanofi
Schering AG
SK Chemicals Co.
Takeda Pharmaceutical
Tolmar Therapeutics
ValiRX
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain Ltd
Advertisement
Forecasts and Analysis of Leading Endometriosis Drugs (Lupron, Eligard, Zoladex, Depo-Provera, Visanne), Companies and Key National Markets
Advertisement
Endometriosis - our new study reveals trends, R&D progress, and predicted revenues
(Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )
Where is the Endometriosis market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.
Discover How to Stay Ahead:
Our 146-page report provides 108 tables, charts, clearly illustrating the data presented in this research. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted drug sales at overall world market regional level, as well as giving a deep insight into the pipeline for Endometriosis. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Endometriosis market. See how to exploit the opportunities.
Forecasts to 2027 and other analyses reveal the commercial prospects
In addition to revenue forecasting to 2027, our new study provides you with recent results, R&D overview, growth rates, and market shares.
You find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and following Endometriosis Therapeutics:
Lupron
Eligard
Zoladex
Depo-Provera
Visanne
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 11 leading national markets:
The US
Germany
France
The UK
Spain
Italy
Japan
China
India
Brazil
Russia
RoW
Endometriosis Drug Forecasts and R&D 2017-2027
The report also includes profiles and pipeline analysis for some of the leading companies in the Endometriosis market, with a focus on the Endometriosis segment of these companies' operations.
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, Germany, France and India in particular, will continue to achieve high revenue growth to 2027.
Leading companies and the potential for market growth
Overall world revenue for Endometriosis will surpass $3bn in 2027, our work calculates. This will be driven by the development of more effective drugs for the condition as well as raising awareness of Endometriosis over the forecast period
Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Endometriosis Market report helps you
In summary, our 146-page report provides you with the following knowledge:
Revenue forecasts to 2027 for the Endometriosis market and 5 Leading Therapeutic Drugs for the condition - discover the industry's prospects, finding the most lucrative places for investments and revenues
Revenue forecasts to 2027 for 11 of the leading national markets - US, Germany, France, UK, Italy, Spain, Russia, Japan, China, India, Brazil
Discussion of what stimulates and restrains companies and the market
Prospects for established firms and those seeking to enter the market - including company profiles and R&D overviews for 10 companies involved in developing and manufacturing Endometriosis drugs
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the Endometriosis market and leading companies. You will find data, trends and predictions.
Get our report today Endometriosis Drug Forecasts and R&D 2017-2027: Forecasts and Analysis of Leading Endometriosis Drugs (Lupron, Eligard, Zoladex, Depo-Provera, Visanne), Companies and Key National Markets. Avoid missing out - get our report now.
To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100
Or click on https://www.visiongain.com/Report/1957/Endometriosis-Drug-Forecasts-and-R-D-2017-2027
Companies Mentioned in This Report:
Abbott Laboratories
AbbVie
Ablynx NV
AC Immune SA
Active Biotech AB
Addex Therapeutics Ltd.
Advanced Biological Laboratories SA
AEterna Zenaris
Agenus Schweiz AG
Agios Pharmaceuticals, Inc.
Aileron Therapeutics, Inc.
Akari Therapeutics Plc
Allergan Plc
Amanouchi Pharmaceutical Co.
Amgen, Inc.
Anacor Pharmaceuticals, Inc.
AP Avadis Biotechnologies
Apeiron Biologics Ag
Apogenix GmbH
Aquinox Pharmaceuticals, Inc.
ArQule, Inc.
Array BioPharma, Inc.
Astellas Pharma
AstraZeneca Plc
Atrix Laboratories
Bayer HealthCare
BeiGene Ltd.
BioAtla LLC
Biogen, Inc.
BioNTech AG
BioPorto A/S
Bio-Rad Laboratories, Inc.
Celgene Corp.
Celmatix Inc.
CEL-SCI Corp.
Cepheid
Cidara Therapeutics, Inc.
Cogstate Ltd.
Collplant Holdings Ltd.
CRISPR Therapeutics AG
CTI BioPharma Corp.
Cyprotex Plc
CytomX Therapeutics, Inc.
Debiopharm International Sa
DelsiTech Ltd.
Domain Therapeutics SA
Dongkook Pharmaceutical Co.
ElexoPharm GmbH
Eli Lilly
Enanta Pharmaceuticals, Inc.
EndoCeutics
Epizyme, Inc.
Euroscreen S.A.
Euthymics Bioscience Inc.
Evotec AG
Florida Hospital
Fujisawa Pharmaceutical Co.
Genentech, Inc.
Genzyme Corporation
GlaxoSmithKline
Halozyme Therapeutics, Inc.
HemoShear Therapeutics LLC
Highland Clinical Research
Hydra Biosciences Inc.
Idera Pharmaceuticals, Inc.
ImmunoGen, Inc.
Immunomedics, Inc.
Inc. Forendo Pharma Oy
Infinity Pharmaceuticals, Inc.
Interleukin Genetics, Inc.
Invivo Therapeutics Holdings Corp.
Isifer AB
Jiangsu Kanion Pharmaceutical Co.
Kissei Pharmaceutical
Lipicard Technologies Limited
Medigene AG
Meditrina Pharmaceuticals
Medivation, Inc.
Mendel Biotechnology Inc.
MorphoSys AG
Mylan NV
Myovant Sciences Ltd.
Neurocrine Biosciences, Inc.
NextCure Inc.
ObsEva
OncoMed Pharmaceuticals, Inc.
OncoTherapy Science, Inc.
OPKO Health, Inc.
Orphagen Pharmaceuticals
Peptidream Inc.
Pfizer
Philogen
Philogen Spa
Portola Pharmaceuticals, Inc.
PregLem SA
Probiodrug AG
pSivida Corp.
Puma Biotechnology, Inc.
Repros Therapeutics Inc.
Roche
Sanofi
Schering AG
SK Chemicals Co.
Takeda Pharmaceutical
Tolmar Therapeutics
ValiRX
To see a report overview please email Sara Peerun on [email protected]
SOURCE Visiongain Ltd
